Legend Biotech (LEGN) Return on Invested Capital (2020 - 2026)
Legend Biotech's (LEGN) quarterly Return on Invested Capital came in at 0.0% in Q1 2026, little changed YoY from 0.0% in Q1 2025, and up 25.5% on a QoQ basis from 0.0% in Q3 2025.
Legend Biotech (LEGN) Return on Invested Capital (2020 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Return on Invested Capital data on file, last reported at 0.0% in Q1 2026.
- Quarterly Return on Invested Capital changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2024 annual result came in at 0.01%, down 2.0% from the prior year.
- Return on Invested Capital improved to 0.0% in Q1 2026, from 0.0% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.97% in Q4 2023 to a low of 0.01% in Q1 2022.
- A 5-year average of 0.22% and a median of 0.0% in 2023 frame the typical range for Return on Invested Capital.
- Annual changes were most pronounced in 2023 — Return on Invested Capital jumped 96 bps — and 2024, when it tumbled 96 bps.
- Tracing LEGN's Return on Invested Capital over 5 years: stood at 0.0% in 2022, then soared by 221975 bps to 0.97% in 2023, then slumped by 100 bps to 0.0% in 2024, then sank by 65 bps to 0.0% in 2025, then increased by 25 bps to 0.0% in 2026.
- The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q3 2025), and 0.0% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.78% |
| Jun 30, 2024 | 0.80% |
| Mar 31, 2024 | 0.91% |
| Dec 31, 2023 | 0.97% |
| Sep 30, 2023 | 0.01% |
| Jun 30, 2023 | 0.01% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | -0.02% |
| Sep 30, 2021 | -0.06% |
| Jun 30, 2021 | -0.22% |